Welcome to our dedicated page for Champions Oncolo SEC filings (Ticker: CSBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Champions Oncology, Inc. (NASDAQ: CSBR) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology research services and data businesses. Its common stock is registered on The Nasdaq Stock Market LLC, and the company reports financial and operational information under the Exchange Act. On this page, Stock Titan aggregates CSBR’s SEC filings and applies AI-powered summaries to help interpret the disclosures.
Current reports on Form 8-K from Champions Oncology frequently present results of operations and financial condition, including quarterly and annual oncology revenue, oncology services profit and oncology services margin, along with reconciliations of non-GAAP measures such as adjusted EBITDA and adjusted EPS to GAAP net income and earnings per share. Other 8-K filings describe corporate events such as the appointment of a new Chief Executive Officer, related employment agreements and leadership transitions at the board level.
The company’s definitive proxy statement on Schedule 14A outlines governance and compensation matters, including the election of directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation. It also describes the annual meeting process and voting requirements for stockholders.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, referenced in the company’s press releases, contain audited and unaudited financial statements, segment information related to oncology revenue and additional details on research services and data license revenue. Stock Titan’s CSBR filings page provides real-time access to these documents as they are posted to EDGAR, while AI-generated highlights help users quickly locate key topics such as non-GAAP reconciliations, oncology services margins, leadership changes and shareholder voting items.
Champions Oncology reported slightly lower quarterly oncology revenue of $16.6M, down from $17.0M a year ago, and swung to a net loss of $0.3M compared with prior net income of $4.5M. Higher outsourced lab work, especially radiolabeling, plus increased research, sales, and administrative spending drove costs up faster than revenue.
For the nine months ended January 31, 2026, revenue rose modestly to $45.6M from $44.6M, but results moved from net income of $6.5M to a net loss of $0.5M. The company used $2.5M of cash in operations and ended the period with $7.1M in cash, negative working capital of about $0.5M, and an accumulated deficit of roughly $80.4M. Management nevertheless believes existing cash and expected operating cash flows can fund operations through at least March 2027.
Champions Oncology reported third quarter fiscal 2026 oncology revenue of $16.6 million, slightly below the prior year’s $17.0 million as a large $4.5 million data license from last year did not repeat. Study service revenue still grew about 32%, reflecting strong project execution.
The company posted a GAAP net loss of $279,000 versus net income of $4.5 million a year earlier, while adjusted EBITDA fell to $574,000 from $5.1 million as oncology services margin declined to 47% from 61% due to higher outsourced lab costs and mix shift.
For the nine months ended January 31, 2026, revenue edged up to $45.6 million from $44.6 million, but results swung to a net loss of $508,000 from $6.5 million of net income, with adjusted EBITDA decreasing to $1.5 million from $8.3 million. Champions ended the quarter with $7.1 million in cash and no debt, while increasing investment in R&D, sales and marketing, and its data platform to support future growth.
Champions Oncology (CSBR) CEO and director Robert L. Brainin received several option grants to buy common stock at an exercise price of $7.80 per share on July 16, 2025, expiring on July 16, 2035.
The awards include time-based vesting, where 25% vests on July 16, 2026 and the rest monthly over three years, plus multiple performance-based tranches. These performance options vest only if the company reaches EBITDA of $25 million or $35 million over any four-quarter period, achieves data revenue of $15 million or $30 million over any four-quarter period, or maintains a 45‑day average stock price at or above strike prices of $16.00 and $24.00.
Champions Oncology director Robert Lawrence Brainin reported multiple stock option awards over several years. The Form 4 shows options to purchase common stock granted on November 5, 2021, November 1, 2022, November 3, 2023, and November 12, 2024, at exercise prices of $10.10, $7.00, $5.51, and $4.64 per share, respectively.
Each grant vests over twelve months in four installments on specified quarterly dates. After the most recent November 12, 2024 award of 23,030 options, Brainin beneficially owned 74,163 stock options directly, all expiring ten years from their respective grant dates.
Champions Oncology, Inc. director Robert Lawrence Brainin filed an initial ownership report showing a stock option holding. He holds an option to purchase 8,032 shares of common stock at an exercise price of $9.27 per share, expiring on June 9, 2031. The option vests over a two‑month period, with 6,024 options vesting on June 9, 2021 and 2,008 options vesting on August 9, 2021, and is held directly.
Champions Oncology reported higher revenue but weaker profitability for the quarter ended October 31, 2025. Oncology revenue grew to $15,035,000 from $13,489,000, an 11.5% increase, driven mainly by pharmacology services, which rose to $14,515,000 from $12,498,000. TOS data license revenue contributed $157,000 versus none a year ago, while other TOS revenue declined to $363,000 from $991,000 as flow cytometry and SaaS activity fell.
Income from operations for the quarter declined to $185,000 from $732,000, and net income attributable to common shares was $268,000 versus $728,000, or $0.02 per diluted share compared with $0.05. For the six months, oncology revenue increased to $29,030,000, but results swung to a loss from operations of $342,000 and a net loss attributable to common shares of $169,000, compared with income of $2,061,000 and $2,041,000, respectively, a year earlier. Higher research and development, sales and marketing, and general and administrative expenses reflect investment in the company’s data licensing platform and its Corellia target-discovery subsidiary. Cash was $8,516,000 with negative operating cash flow of $1,135,000, yet management believes existing cash and expected cash flows can fund operations through at least December 2026.
Champions Oncology, Inc. filed a current report to disclose that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.
The press release is attached as Exhibit 99.1, and the company states that the financial information described under Item 2.02 is being furnished rather than filed, and will only be incorporated into other securities filings if specifically referenced.
Champions Oncology (CSBR) reported a Form 4 showing a director was granted an option to purchase 13,790 shares of common stock on November 5, 2025 at an exercise price of $6.8 per share. The option has a ten-year term expiring on November 5, 2035.
The award vests over twelve months in four tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. Following the grant, the reporting person holds 13,790 derivative securities directly.
Champions Oncology (CSBR) reported an insider equity grant on a Form 4. Director David Sidransky was awarded an option to purchase 21,216 shares on 11/05/2025 at an exercise price of $6.8 per share, expiring on 11/05/2035.
The filing lists the transaction code as A (grant). The option was acquired in direct ownership. Vesting is scheduled over twelve months, with tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. The option is exercisable over a ten‑year period.
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.